Dr. Bill Lundberg
Dr. Bill Lundberg is the current President and CEO of Merus N.V., a company that is developing antibodies to treat cancer. He serves as Independent Director of Vor Biopharma, Q32 Bio, and 1928 Diagnostics AB. Previously, Bill was the Chief Scientific Officer at CRISPR Therapeutics. Bill received a Bachelor of Science degree in Biology from the Massachusetts Institute of Technology, M.B.A. from UMass Amherst, M.D. from Stanford University and clinical training in Internal Medicine and Medical Oncology from the Brigham and Women’s Hospital and Dana-Farber Cancer Institute.